ABOUT AVIDITY
Our mission is to profoundly improve people’s lives by delivering a new class of RNA therapeutics – AOCs. Our proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Our advancing and expanding pipeline includes multiple skeletal muscle programs. We are also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution.
News Releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
August 9, 2022
Company remains on track to have three programs in the clinic by the end of this year Programs are for three distinct rare diseases - myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular...
-
August 2, 2022
Adults with myotonic dystrophy type 1 (DM1) in the AOC 1001 Phase 1/2 MARINA™ clinical trial can receive continuity of care as part of MARINA-OLE™ Preliminary assessment of safety,...
-
June 17, 2022
Oral Presentation at FSHD IRC highlights preclinical data that demonstrated prevention of muscle weakness by reducing DUX4 expression AOC 1020 on track to be in the clinic by end of 2022 for the...
-
June 9, 2022
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced...
-
May 10, 2022
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced...